Acute myeloid leukaemia optimising treatment in elderly patients

Drugs and Aging

Volumn 19, Issue 8, 2002, Pages 571-581

  Jackson, Graham H ^a   Taylor, Penelope R A ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; TIOGUANINE; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGING; APNEA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHILL; COMORBIDITY; DEPRESSION; DIARRHEA; DRUG TOLERABILITY; ECZEMA; FEVER; HUMAN; HYPERTENSION; INCIDENCE; LIVER DISEASE; NEUROTOXICITY; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL;

EID: 0036393682     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219080-00003     Document Type: Review

References (43)

1. Northern Region Haematology Group. Annual Report. England: Northern Region Haematology Group, 2000
2. Johnson PRE, Hunt LP, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993; 85: 300-6
3. Burge PS, Richards JDM, Thompson DS, et al. Quality and quantity of survival in acute myeloid leukaemia. Lancet 1975; 2: 621-4
4. Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose Ara-C. Am J Clin Oncol 1998; 21: 142-4
5. Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2 (7): 403-12
6. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92 (7): 2322-33
7. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 2001; 58 (18): 4173-9
8. Buchner T, Hiddemann W, Wormann B, et al. Late events in AML. Data from long-term observation of patients in two trials starting in 1981 and 1985 [abstract]. Blood 1997; 90 (10): 504a
9. Taylor P, Bown N, Cuthbert G, et al. A population based study of de-novo AML to assess karyotype incidence pattern and its impact on survival by age cohorts [abstract]. Ann Haematol 2001; 80: S19
10. Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14 (4): 1345-52
11. Proctor SJ, Taylor PRA. Age cohort subgroups in adult acute myeloid leukaemia studies: the population perspective. Leukemia 2001; 15 (1): 188-9
12. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8; 21)(q22; q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996; 10 (8): 1288-95
13. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89 (9): 3323-9
14. Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in actue myelogenous leukaemia of the elderly. Br J Haematol 2001; 92 (3): 627-31
15. Behringer B, Kunzmann R, Schmoor C, et al. Serum lactate dehydrogenase (LDH) as an independent prognostic factor for overall survival in patients with acute myeloid leukemia (AML) aged > 55 years [abstract]. Blood 2000; 96 (11): 123a
16. Taylor PRA, Reid MM, Stark AN, et al. De-novo acute myeloid leukaemia in patients over 55 years old: a population based study of incidence, treatment and outcome. Leukemia 1995; 9 (2): 231-7
17. Rees JKH, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; II: 1236-41
18. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukaemia: a Cancer and Leukemia Group B study. Blood 1987; 69 (5): 1441-9
19. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78 (10): 2520-6
20. Liu Yin JA, Johnson PRE, Davies JM, et al. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415-20
21. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331 (14): 896-903
22. Lowenberg B, Suciu S, Archimbaud E, et al. Mitroxantrone vs daunorubicin in induction-consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly. J Clin Oncol 1998; 16 (3): 872-81
23. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin of adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60 (2): 454-62
24. Kahn SB, Begg CB, Mazza JJ, et al. Full dose vs attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984; 2 (8): 865-70
25. Baudard M, Marie JP, Cadiou M, et al. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91
26. Pulsoni A, Pagano L, Tosti ME, et al. Retrospective survival analysis of elderly patients with acute myeloid leukemia (aml) treated with aggressive or non aggressive therapy [abstract]. Blood 2000; 96 (11): 2166a
27. Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukaemia cells. Cancer Res 1988; 48: 329-34
28. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarbine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes: comparison with fludarabine plus cytarbine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12 (4): 671-8
29. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001; 112: 127-37
30. Arlin Z, Case Jr DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphoctytic leukemia (ANLL). Leukemia 1990; 4 (3): 177-83
31. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103 (4): 620-5
32. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72 (2): 567-72
33. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94 (4): 1192-200
34. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981; 58: 1203-11
35. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects. Blood 2001; 97 (11): 3390-400
36. Groot C-D, Lowenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1998; 100 (4): 629-36
37. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90 (12): 4710-8
38. Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 1994; 8 (1): 11-5
39. Jackson GH, Taylor PRA, Iqbal A, et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia 1997; 11: 1193-6
40. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 1990; 8 (2): 272-9
41. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtruzumab ozogamicin in patients with CD-33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19 (13): 3244-54
42. Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol 1999; 17 (9): 2831-9
43. Wattel E, Solary E, Hecquet B, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing p glycoprotein: results of a randomized study. Br J Haematol 1998; 102: 1015-24